Irrigation Fluid Absorption and Perioperative cfDNA Changes in TURBT for Bladder Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort study involving adults with suspected or confirmed urothelial bladder cancer undergoing TURBT. Researchers will measure how much irrigation fluid is absorbed during surgery and collect blood before and within 24 hours after TURBT to analyze cell-free DNA and tumor mutations. They will examine whether irrigation fluid absorption correlates with cfDNA dynamics, tumor characteristics, and perioperative factors, and will follow patients for recurrence, progression, and other outcomes. The study is conducted at The Second Hospital of Lanzhou University in China, led by Zhiping Wang, without an interventional treatment component.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 years or older.
2. Suspected or histologically confirmed urothelial carcinoma of the bladder.
3. Scheduled to undergo TURBT.
4. Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis.
5. Availability of complete clinicopathological and perioperative data.
6. Ability to provide informed consent and comply with study follow-up.

Exclusion Criteria:

1. Non-urothelial bladder malignancy confirmed by pathology.
2. History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
3. Previous radical cystectomy or systemic antitumor therapy before enrollment.
4. Inadequate blood sample quality or insufficient DNA yield for mutation analysis.
5. Pregnancy or breastfeeding.
6. Serious uncontrolled intercurrent illness that may interfere with study participation, follow-up, or compliance, including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, severe psychiatric illness, or other conditions judged by the investigator to make participation unsuitable.

Where it's running

• The Second Hospital of Lanzhou University
  Lanzhou, Gansu, China Recruiting

Study contacts

• Principal investigator: Zhiping Wang — Lanzhou University Second Hospital

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mass spectrometry test to detect multiple gene mutations in bladder cancer

  This project will try a nucleic-acid mass spectrometry test on tumor and matched normal tissue to detect many clinically relevant gene mutations in adults with bladder cancer.

  Recruiting Lanzhou University Second Hospital · Lanzhou, Gansu · NCT07424560

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Perioperative systemic therapies in muscle-invasive bladder cancer (GUARDIANS)

  This registry will see how real-world perioperative treatments for muscle-invasive bladder cancer work in adults, including regimens like Enfortumab Vedotin with Pembrolizumab and cisplatin-based plans.

  Recruiting LMU Klinikum · Munich · NCT07855926

• Cyclic Sighing Breathing to Help with Discomfort, Pain, and Sleep After TUR

  This study tests whether a short cyclic sighing breathing exercise after TUR surgery can reduce catheter-related bladder discomfort and pain and improve sleep.

  Recruiting Mersin University · Hatay and 1 other locations · NCT07843602

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.